AR043405A1 - SPECIFIC HUMAN ANTIBODIES FOR INTERLEUQUINE 15 (IL-15) - Google Patents
SPECIFIC HUMAN ANTIBODIES FOR INTERLEUQUINE 15 (IL-15)Info
- Publication number
- AR043405A1 AR043405A1 ARP040100605A AR043405A1 AR 043405 A1 AR043405 A1 AR 043405A1 AR P040100605 A ARP040100605 A AR P040100605A AR 043405 A1 AR043405 A1 AR 043405A1
- Authority
- AR
- Argentina
- Prior art keywords
- human
- antibodies
- homologous
- human antibodies
- disclosed
- Prior art date
Links
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 abstract 3
- 102000056003 human IL15 Human genes 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000009261 transgenic effect Effects 0.000 abstract 2
- 102000003812 Interleukin-15 Human genes 0.000 abstract 1
- 108090000172 Interleukin-15 Proteins 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000005215 recombination Methods 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011830 transgenic mouse model Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se revelan anticuerpos monoclonales humanos aislados que se unen especialmente a la IL-15 (por ejemplo la IL-15 humana), y composiciones y moléculas relacionadas basadas en anticuerpos. Los anticuerpos humanos se pueden producir en un transfectoma o en un animal transgénico no humano, por ejemplo un ratón transgénico, capaz de producir isotipos múltiples de anticuerpos monoclonales humanos al someterse a un cambio de isotipo y recombinación V-D-J: También se revelan composiciones farmacéuticas que comprenden anticuerpos humanos, animales transgénicos no humanos, e hibridomas que producen los anticuerpos humanos, y métodos terapéuticos y de diagnóstico para utilizar los anticuerpos humanos. Reivindicación 1: Un anticuerpo monoclonal humano aislado que se une especialmente a la IL-15 humana, que comprende al menos una secuencia de CDR seleccionada del grupo formado por: (i) SEC ID Nos: 5, 6, 7, 8, 9, y 10; (ii) secuencias que son al menos 90% homólogas, preferentemente al menos 95% homólogas, y más preferentemente al menos 98%, o al menos 99% homólogas a las secuencias definidas en (i); y (iii) fragmentos de las secuencias definidas en (i) o (ii), que retienen la capacidad de unirse específicamente a la IL-15 humana.Isolated human monoclonal antibodies that bind especially to IL-15 (for example human IL-15), and related antibody-based compositions and molecules are disclosed. Human antibodies can be produced in a transfectome or in a non-human transgenic animal, for example a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing a change of isotype and recombination VDJ: Pharmaceutical compositions are also disclosed comprising human antibodies, non-human transgenic animals, and hybridomas that produce human antibodies, and therapeutic and diagnostic methods for using human antibodies. Claim 1: An isolated human monoclonal antibody that binds especially to human IL-15, comprising at least one CDR sequence selected from the group consisting of: (i) SEQ ID Nos: 5, 6, 7, 8, 9, and 10; (ii) sequences that are at least 90% homologous, preferably at least 95% homologous, and more preferably at least 98%, or at least 99% homologous to the sequences defined in (i); and (iii) fragments of the sequences defined in (i) or (ii), which retain the ability to specifically bind human IL-15.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/374,932 US7329405B2 (en) | 2001-08-23 | 2003-02-26 | Human antibodies specific for interleukin 15 (IL-15) |
US10/379,741 US7247304B2 (en) | 2001-08-23 | 2003-03-05 | Methods of treating using anti-IL-15 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
AR043405A1 true AR043405A1 (en) | 2005-07-27 |
Family
ID=36770634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040100605 AR043405A1 (en) | 2003-02-26 | 2004-02-26 | SPECIFIC HUMAN ANTIBODIES FOR INTERLEUQUINE 15 (IL-15) |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP4892335B2 (en) |
CN (1) | CN1780856A (en) |
AR (1) | AR043405A1 (en) |
EA (1) | EA015897B1 (en) |
RS (1) | RS20050724A (en) |
ZA (1) | ZA200506724B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2769984T (en) | 2007-05-11 | 2017-10-05 | Altor Bioscience Corp | Fusion molecules and il-15 variants |
US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
PT2619229T (en) | 2010-09-21 | 2016-07-13 | Altor Bioscience Corp | Multimeric il-15 soluble fusion molecules and methods of making and using same |
CN102250243B (en) * | 2011-07-01 | 2013-08-28 | 华绍炳 | Antibody to interleukins-15 |
KR20230028807A (en) | 2014-06-30 | 2023-03-02 | 알토 바이오사이언스 코포레이션 | Il-15-based molecules and methods of use thereof |
EP2963057A1 (en) * | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antibodies to IL-15 |
JP2019521981A (en) * | 2016-06-15 | 2019-08-08 | アムジエン・インコーポレーテツド | Methods and compositions for treating celiac disease, non-celiac gluten hypersensitivity and refractory celiac disease |
AU2017345791B2 (en) | 2016-10-21 | 2020-10-22 | Altor Bioscience Corporation | Multimeric IL-15-based molecules |
PE20191497A1 (en) * | 2016-12-21 | 2019-10-21 | Cephalon Inc | ANTIBODIES THAT SPECIFICALLY BIND HUMAN IL-15 AND USES OF THEM |
CN114786479B (en) * | 2019-12-25 | 2023-12-15 | 江苏集萃药康生物科技股份有限公司 | IL-15 humanized mouse model and application thereof |
CN114377133A (en) * | 2022-01-20 | 2022-04-22 | 山东大学 | Targeting renal CD8+Application of TRM formation and activation in glomerular injury |
CN115362984B (en) * | 2022-07-07 | 2024-01-16 | 成都中医药大学 | Construction method of mouse autoimmune thyroiditis model |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795966A (en) * | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
GB9814892D0 (en) * | 1998-07-10 | 1998-09-09 | Kennedy Rheumatology Inst | Treatment of celiac disease |
WO2001002003A1 (en) * | 1999-07-06 | 2001-01-11 | Bulfone Paus Silvia | Method of treating psoriasis with il-15 antagonist |
WO2003017935A2 (en) * | 2001-08-23 | 2003-03-06 | Genmab A/S | Human antibodies specific for interleukin 15 (il-15) |
-
2004
- 2004-02-25 JP JP2006502466A patent/JP4892335B2/en not_active Expired - Lifetime
- 2004-02-25 EA EA200501362A patent/EA015897B1/en not_active IP Right Cessation
- 2004-02-25 RS YUP-2005/0724A patent/RS20050724A/en unknown
- 2004-02-25 ZA ZA200506724A patent/ZA200506724B/en unknown
- 2004-02-25 CN CN 200480011288 patent/CN1780856A/en active Pending
- 2004-02-26 AR ARP040100605 patent/AR043405A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP4892335B2 (en) | 2012-03-07 |
JP2007528348A (en) | 2007-10-11 |
EA200501362A1 (en) | 2006-02-24 |
EA015897B1 (en) | 2011-12-30 |
RS20050724A (en) | 2007-11-15 |
ZA200506724B (en) | 2007-03-28 |
CN1780856A (en) | 2006-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTC3284753I2 (en) | ||
DK1425389T3 (en) | Interleukin-15- (IL-15) -specific human antibodies | |
DE60031279D1 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST PROSTATE SPECIFIC MEMBRANEANT | |
TW200500378A (en) | Human antibodies specific for interleukin 15 (IL-15) | |
BRPI0210405B8 (en) | human monoclonal antibody, bispecific molecule, in vitro method to inhibit the growth of a cell expressing egfr, to induce cytolysis of a cell expressing egfr, and to detect the presence of egfr antigen or a cell expressing egfr in a sample, e, vector of expression | |
ATE531731T1 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) | |
EA200500835A1 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST CD25 | |
NO20053417L (en) | Human monoclonal antibodies to interleukin 8 (IL-8) | |
ATE384744T1 (en) | HUMAN ANTIBODIES AGAINST HER2/NEW | |
AR047372A1 (en) | ANTIBODIES AGAINST MADCAM | |
ATE553131T1 (en) | HUMAN MONOCLONAL ANTIBODIES AGAINST DENDRITIC CELLS | |
AR043405A1 (en) | SPECIFIC HUMAN ANTIBODIES FOR INTERLEUQUINE 15 (IL-15) | |
TH79238A (en) | Human antibodies specific to interleukin 15 (IL-15). | |
TH79238B (en) | Human antibodies specific to interleukin 15 (IL-15). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure | ||
FA | Abandonment or withdrawal | ||
FC | Refusal |